Kanser Hastalarında Taşiaritmiler

Cheng CW, Yang NI, Ng KK, Cherng WJ. Metastatic cardiac tumor presenting as atrial fibrillation in a previously healthy woman: a case report. Medicine. 2017;96:e7649. https://doi.org/10.1097/md.0000000000007649.

Vaduganathan M, Patel NK, Lubitz SA, Neilan TG, Dudzinski DM. A “Malignant” arrhythmia: cardiac metastasis and ventricular tachycardia. Tex Heart Inst J. 2016;43:558–9. https://doi.org/10.14503/thij-15-5189.

Miyake CY, et al. Cardiac tumors and associated arrhythmias in pediatric patients, with observations on surgical therapy for ventricular tachycardia. J Am Coll Cardiol. 2011;58:1903–9. https://doi.org/10. 1016/j.jacc.2011.08.005.

Kilickap S, Barista I, Akgul E, Aytemir K, Aksoy S,Tekuzman G. Early and late arrhythmogenic effects of doxorubicin. South Med J. 2007;100:262–5.https://doi.org/10.1097/01.smj.0000257382.89910.fe.

Kilickap S, et al: Doxorubicin-induced second degree and complete atrioventricular block.Europace 2005;7:227–230.

Tamargo J, Caballero R, Delpon E: Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf 2015;38:129–152.

2 Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231–47. https://doi.org/10.1016/j.jacc.2009.02.050.

Steinherz LJ, Steinherz PG, Tan C: Cardiac failure and dysrhythmias 6–19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995;24:352–361.

Hayek ER, Speakman E, Rehmus E: Acute doxorubicin cardiotoxicity. N Engl J Med 2005;352:2456–2457.

Keung EC, et al: L-type cardiac calcium channels in doxorubicin cardiomyopathy in rats morphological, biochemical, and functional correlations. J Clin Invest 1991; 87: 2108–2113.

Volkova M, Russell R 3rd: Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011;7:214–220.

Perel RD, Slaughter RE, Strugnell WE: Subendocardial late gadolinium enhancement in two patients with anthracycline cardiotoxicity following treatment for Ewing’s sarcoma. J Cardiovasc Magn Reson 2006;8:789–791.

Neilan TG, et al: Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol 2012;110:1679–1686.

Markman TM, Markman M: Cardiotoxicity of antineoplastic agents: what is the present and future role for imaging? Curr Oncol Rep 2014;16:396.

Bello D, et al: Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol 2005;45:1104–1108.

Nazarian S, et al: Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation 2005;112:2821–2825.

Adabag AS, et al: Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51:1369–1374.

Tracy CM, et al: 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Heart Rhythm 2012;9:1737–1753.

Gottdiener JS, et al: Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981;141:758–763.

Curigliano G, et al: Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis 2010;53:94–104.

Moreau P, et al: Melphalan 220 mg/m 2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999;23:1003–1006.

Richards WG, et al: Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006;24:1561–1567.25

Kupari M, et al: Cardiac involvement in bone marrow transplantation: serial changes in left ventricular size, mass and performance. J Intern Med 1990;227:259–266.

Cil T, et al: Cytosine-arabinoside induced bradycardia in patient with non-Hodgkin lymphoma: a case report. Leuk Lymphoma 2007;48:1247–1249.

Quezado ZM, et al: High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993;118:31–36.

Guglin M, et al: Introducing a new entity: chemotherapy-induced arrhythmia. Europace 2009;11:1579–1586.

Alloatti G, et al: Differential effects of paclitaxel and derivatives on guinea pig isolated heart and papillary muscle. J Pharmacol Exp Ther 1998;284:561–567.

Rowinsky EK, et al: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993;20(4 suppl 3):1–15.

McGuire WP, et al: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273–279.

Bristow MR, et al: Acute and chronic cardio-vascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol 1980;2:487–515.

Kietpeerakool C, et al: Benefit of electrocardiography during front-line combination paclitaxel and carboplatin chemotherapy for epithelial ovarian cancer. J Med Assoc Thai 2006;89:1805–1810.

Rezkalla S, et al: Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989;7:509–514.

Williams SF, Larson RA: Hypersensitivity reaction to high-dose cytarabine. Br J Haematol 1989;73:274–275.

Talapatra K, et al: Transient asymptomatic bradycardia in patients on infusional 5-fluorouracil. J Cancer Res Ther 2007;3:169–171.

Pogwizd SM, Corr PB: Electrophysiologic mechanisms underlying arrhythmias due to reperfusion of ischemic myocardium. Circulation 1987;76:404–426.

Saif MW, Shah MM, Shah AR: Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009;8:191–202.

Eskilsson J, Albertsson M: Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol 1990;29:1001–1003.

Strevel EL, Ing DJ, Siu LL: Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007;25:3362–3371.

Lenihan DJ, Kowey PR: Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist 2013;18:900–908.

Thavendiranathan P, et al: Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging 2013;6:1080–1091.

Schmidinger M, et al: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26:5204–5212.

Unnikrishnan D, et al: Cardiac monitoring of patients receiving arsenic trioxide therapy. Br J Haematol 2004;124:610–617.

Huang SY, et al: Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 1998;103:1092–1095.

Ohnishi K, et al: Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 2002;16:617–622.

Beer TM, et al: Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer 2006;106:2624–2629.

Westervelt P, et al: Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001;98:266–271.

Ficker E, et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol.2004;66:33–44. https://doi.org/10.1124/mol.66.1.33.

Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol. 2014;63:945–53.

Onaitis M, D’Amico T, Zhao Y, et al. Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database. Ann Thorac Surg. 2010;90:368–74.

Guzzetti S, Costantino G, Vernocchi A, et al. First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation. Intern Emerg Med. 2008;3:227–31.

Erichsen R, Christiansen CF, Mehnert F, et al. Colorectal cancer and risk of atrial fibrillation and flutter: a population-based case–control study. Intern Emerg Med. 2012;7:431–8.

O’Neal WT, Lakoski SG, Qureshi W, et al. Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study). Am J Cardiol. 2015;115:1090–4. This is the first study to demonstrate elevated rates of atrial fibrillation in patients with non-life-threatening cancers independent of traditional risk factors for this arrhythmia.

Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108:3006–10.

Writing Group M, Lloyd-Jones D, Adams RJ, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–215.

Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.

de Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol. 1992;10:1795–801.

Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39:974–84.

Bischiniotis TS, Lafaras CT, Platogiannis DN, et al. Intrapericardial cisplatin administration after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade. Hell J Cardiol. 2005;46:324–9.

Gorelik J, Vodyanoy I, Shevchuk AI, et al. Esmolol is antiarrhythmic in doxorubicin-induced arrhythmia in cultured cardiomyocytes—determination by novel rapid cardiomyocyte assay. FEBS Lett. 2003;548:74–8.

Binah O, Cohen IS, Rosen MR. The effects of adriamycin on normal and ouabain-toxic canine Purkinje and ventricular muscle fibers. Circ Res. 1983;53:655–62.

Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol. 1991;9:694–704.

Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889–97.

Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol. 1989;7:7–20.

Margolin KA, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol.1989;7:486–98. https://doi.org/10.1200/jco.1989.7.4.486.

Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172–87.

Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011–9.

Mego M, Reckova M, Obertova J, et al. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann Oncol. 2007;18:1906–7.

Xu Z, Cang S, Yang T, Liu D. Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy. Hematol Reviews. 2009;1:17–21.

Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16.

Johnson JN, Ackerman MJ. QTc: how long is too long? Br J Sports Med. 2009;43:657–62. https://doi.org/10.1136/bjsm.2008.054734.

Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739–45.

Craxton A, Jiang A, Kurosaki T, Clark EA. Syk and Bruton’s tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt. J Biol Chem. 1999;274:30644–50.

McMullen JR, Boey EJ, Ooi JY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124:3829–30. This study suggested potential mechanisms for atrial fibrillation associated with ibrutinib use.

Pretorius L, Du XJ, Woodcock EA, et al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am J Pathol. 2009;175:998–1009.

Chong E, Chang SL, Hsiao YW, et al. Resveratrol, a red wine antioxidant, reduces atrial fibrillation susceptibility in the failing heart by PI3K/AKT/eNOS signaling pathway activation. Heart Rhythm. 2015;12:1046–56.

Singhal R, Chang SL, Chong E, et al. Colchicine suppresses atrial fibrillation in failing heart. Int J Cardiol. 2014;176:651–60.

Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.

Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008–18.

Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117:591–4.

Byrd JC, Harrington B, O’Brien S et al. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 2015

Singla A, Hogan WJ, Ansell SM, et al. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:1233–7.

Tonorezos ES, Stillwell EE, Calloway JJ, et al. Arrhythmias in the setting of hematopoietic cell transplants. Bone Marrow Transplant. 2015;50:1212–6. This study reported significant adverse outcomes including increased mortality in patients undergoing stem cell transplant who develop atrial fibrillation.

Feliz V, Saiyad S, Ramarao SM, et al. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol. 2011;34:356–9.

Peres E, Levine JE, Khaled YA, et al. Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010;45:149–52.

Sureddi RK, Amani F, Hebbar P, et al. Atrial fibrillation following autologous stem cell transplantation in patients with multiple myeloma: incidence and risk factors. Ther Adv Cardiovasc Dis. 2012;6:229–36.

Naing A, Veasey-Rodrigues H, Hong DS, et al. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol. 2012;23:2960–3.

Curigliano G, Spitaleri G, de Braud F, et al. QTc prolongation assessment in anticancer drug development: clinical and methodological issues. Ecancer Med Sci. 2009;3:130.

Brell JM. Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy. Prog Cardiovasc Dis. 2010;53:164–72.

Fradley MG, Moslehi J. QT prolongation and oncology drug development. Card Electrophysiol Clin. 2015;7:341–55.

Hu J, Shen ZX, Sun GL, et al. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-transretinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution. Int J Hematol. 1999;70:248–60.

Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.N Engl J Med. 1998;339:1341–8.

Weinberg SL. The electrocardiogram in acute arsenic poisoning. Am Heart J. 1960;60:971–5.

Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003;21:3609–15. https://doi.org/10.1200/jco.2003.10.009.

Roboz GJ, Ritchie EK, Carlin RF, et al. Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide. J Clin Oncol. 2014;32:3723–8.

Barbey JT. Cardiac toxicity of arsenic trioxide. Blood. 2001;98:1632. author reply 1633–1634.

Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36:295–316.

Lu Z, Wu CY, Jiang YP, et al. Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci Transl Med. 2012;4:131ra150.

Morgan Jr TK, Sullivan ME. An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy. Prog Med Chem. 1992;29:65–108.

Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS One. 2012;7, e30353.

Tamura T, Minami H, Yamada Y, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol. 2006;1:1002–9.

Kiura K, Nakagawa K, Shinkai T, et al. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol. 2008;3:386–93.

Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol.2011;29:1059–66.

Locatelli M, Criscitiello C, Esposito A, et al. QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review. Target Oncol. 2015;10:27–43.

Tam CS, Kantarjian H, Garcia-Manero G, et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood.2008;112:516–8.

Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542–51.

Shultz MD, Cao X, Chen CH, et al. Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. J Med Chem. 2011;54:4752–72.

Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109–15.

Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006;12:3762–73.